Literature DB >> 12937416

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

Mériam Belghith1, Jeffrey A Bluestone, Samia Barriot, Jérôme Mégret, Jean-François Bach, Lucienne Chatenoud.   

Abstract

CD3-specific antibodies have the unique capacity to restore self-tolerance in established autoimmunity. They induce long-term remission of overt diabetes in nonobese diabetic (NOD) mice and in human type I diabetes. The underlying mechanisms had been unclear until now. Here we report that treatment with CD3epsilon-specific antibodies induces transferable T-cell-mediated tolerance involving CD4+CD25+ cells. However, these CD4+CD25+ T cells are distinct from naturally occurring regulatory T cells that control physiological autoreactivity. CD3-specific antibody treatment induced remission in NOD Cd28-/- mice that were devoid of such regulatory cells. Remission of diabetes was abrogated by coadministration of a neutralizing transforming growth factor (TGF)-beta-specific antibody. The central role of TGF-beta was further suggested by its increased, long-lasting production by CD4+ T cells from tolerant mice. These data explain the intriguing tolerogenic effect of CD3-specific antibodies and position them as the first clinically applicable pharmacological stimulant of TGF-beta-producing regulatory CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937416     DOI: 10.1038/nm924

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  213 in total

Review 1.  TGF-beta, T-cell tolerance and anti-CD3 therapy.

Authors:  Ramireddy Bommireddy; Thomas Doetschman
Journal:  Trends Mol Med       Date:  2004-01       Impact factor: 11.951

2.  Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3.

Authors:  Lars Kjer-Nielsen; Michelle A Dunstone; Lyudmila Kostenko; Lauren K Ely; Travis Beddoe; Nicole A Mifsud; Anthony W Purcell; Andrew G Brooks; James McCluskey; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

Review 3.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

4.  Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes.

Authors:  Stuart E Turvey; Eric Swart; Maria C Denis; Umar Mahmood; Christophe Benoist; Ralph Weissleder; Diane Mathis
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

Review 5.  Induced regulatory T cells: mechanisms of conversion and suppressive potential.

Authors:  Eefje M Dons; Giorgio Raimondi; David K C Cooper; Angus W Thomson
Journal:  Hum Immunol       Date:  2012-01-14       Impact factor: 2.850

Review 6.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

7.  Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration.

Authors:  Y Maurice Morillon; Elizabeth Chase Lessey-Morillon; Matthew Clark; Rui Zhang; Bo Wang; Keith Burridge; Roland Tisch
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

Review 8.  Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.

Authors:  Prabhakaran Kumar; Shikha Saini; Saad Khan; Swarali Surendra Lele; Bellur S Prabhakar
Journal:  Cell Immunol       Date:  2018-09-29       Impact factor: 4.868

9.  Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.

Authors:  Baowei Peng; Peiqing Ye; David J Rawlings; Hans D Ochs; Carol H Miao
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

10.  AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice.

Authors:  Khaja K Rehman; Massimo Trucco; Zhong Wang; Xiao Xiao; Paul D Robbins
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.